AU2012340563B2 - L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders - Google Patents

L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders Download PDF

Info

Publication number
AU2012340563B2
AU2012340563B2 AU2012340563A AU2012340563A AU2012340563B2 AU 2012340563 B2 AU2012340563 B2 AU 2012340563B2 AU 2012340563 A AU2012340563 A AU 2012340563A AU 2012340563 A AU2012340563 A AU 2012340563A AU 2012340563 B2 AU2012340563 B2 AU 2012340563B2
Authority
AU
Australia
Prior art keywords
serine
bmaa
disease
day
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012340563A
Other languages
English (en)
Other versions
AU2012340563A1 (en
Inventor
Paul A. Cox
Rachael DUNLOP
Kenneth Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for EthnoMedicine
Original Assignee
Institute for EthnoMedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for EthnoMedicine filed Critical Institute for EthnoMedicine
Publication of AU2012340563A1 publication Critical patent/AU2012340563A1/en
Assigned to THE INSTITUTE FOR ETHNOMEDICINE reassignment THE INSTITUTE FOR ETHNOMEDICINE Amend patent request/document other than specification (104) Assignors: DUNLOP RACHAEL, KENNETH RODGERS, PAUL A. COX, THE INSTITUTE FOR ETHNOMEDICINE
Application granted granted Critical
Publication of AU2012340563B2 publication Critical patent/AU2012340563B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012340563A 2011-11-21 2012-11-21 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders Active AU2012340563B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562194P 2011-11-21 2011-11-21
US61/562,194 2011-11-21
PCT/US2012/066373 WO2013078395A1 (en) 2011-11-21 2012-11-21 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Publications (2)

Publication Number Publication Date
AU2012340563A1 AU2012340563A1 (en) 2014-05-29
AU2012340563B2 true AU2012340563B2 (en) 2017-01-19

Family

ID=48470319

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012340563A Active AU2012340563B2 (en) 2011-11-21 2012-11-21 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Country Status (10)

Country Link
US (5) US20130156846A1 (https=)
EP (1) EP2782566B1 (https=)
JP (1) JP6265908B2 (https=)
AU (1) AU2012340563B2 (https=)
CA (1) CA2855854C (https=)
DK (1) DK2782566T3 (https=)
ES (1) ES2856063T3 (https=)
IL (1) IL232710B (https=)
PT (1) PT2782566T (https=)
WO (1) WO2013078395A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006748A (es) * 2014-11-24 2017-08-28 Entrinsic Health Solutions Inc Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
US10960076B2 (en) 2017-01-25 2021-03-30 Church & Dwight Co. Inc. Gummy dosage forms comprising serine
KR20180101242A (ko) 2017-03-02 2018-09-12 주식회사 아스트로젠 엘­세린을 유효성분으로 포함하는 혈뇌장벽 장애의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
AU2019282362B2 (en) * 2018-06-08 2025-04-03 The Institute For Ethnomedicine Method of enhancing glucose levels in the central nervous system
KR101952443B1 (ko) * 2018-08-23 2019-02-26 주식회사 아스트로젠 신규한 마그네슘­세리네이트 화합물 및 이의 용도
KR102022118B1 (ko) * 2019-01-07 2019-09-18 주식회사 아스트로젠 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물
AU2020334128B2 (en) * 2019-08-21 2025-10-23 Brain Chemistry Labs Compositions comprising a metal and L-serine, and uses thereof
US12578348B2 (en) * 2021-02-05 2026-03-17 The Institute For Ethnomedicine Blood indicators of Alzheimer's disease
CN112972458B (zh) * 2021-03-05 2022-10-04 北京北科华夏生物医药科技有限公司 一种组合物在制备阿尔兹海默症治疗药物中的应用
KR102522508B1 (ko) * 2022-12-16 2023-04-18 주식회사 아스트로젠 마그네슘-세리네이트의 신규한 결정형 및 이의 제조방법
WO2025014008A1 (ko) * 2023-07-07 2025-01-16 주식회사 아스트로젠 질환의 치료 방법
KR20250081156A (ko) * 2023-11-29 2025-06-05 주식회사 아스트로젠 L-세린 염산염의 제조 방법 및 이의 용도
CN118303636A (zh) * 2024-04-12 2024-07-09 南通大学 一种改善帕金森症状的功能性食品
KR20260010331A (ko) * 2024-07-12 2026-01-20 주식회사 아스트로젠 L-세린의 리포좀 제형 및 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287204A1 (en) * 2002-06-19 2005-12-29 Hageman Robert J J Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873722A (en) 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
US4000318A (en) * 1974-08-19 1976-12-28 Commonwealth Scientific And Industrial Research Organization Amino acid supplements
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
JPS6440453A (en) 1987-08-05 1989-02-10 Mitsui Toatsu Chemicals Racemization of optically active serine
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
SE502280C2 (sv) 1991-12-20 1995-09-25 Bio Swede Ab Separering av aminosyror, aminosyrabaserad monomer och förfarande för framställning därav samt polymert material och förfarande för framställning därav
WO1996015788A1 (en) 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
CA2298795A1 (en) * 1997-07-28 1999-02-04 The Institute Of Physical And Chemical Research Agent for protecting central nerve cells and enhancing survival thereof
EP1073432B1 (en) 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia
US6984484B1 (en) * 1999-01-19 2006-01-10 The Johns Hopkins University Mammalian serine racemase
JP2002316929A (ja) * 2001-04-18 2002-10-31 Japan Science & Technology Corp Ｌ−セリン又はグリシンからなる抗アポトーシス剤
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US20050028720A1 (en) * 2003-08-05 2005-02-10 Bell Adam Warwick Pop-up device for deterring an attacking animal such as a bear
US7256002B2 (en) 2003-08-12 2007-08-14 The Institute For Ethnomedicine Screening for neurotoxic amino acid associated with neurological disorders
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
FI121915B (fi) 2004-02-06 2011-06-15 Neurofood Ab Oy Koostumus psoriasiksen hoitoon
US20080027088A1 (en) 2004-03-26 2008-01-31 Warner-Lambert Company, Llc Imidazole-Based Hmg-Coa Reductase Inhibitors
CA2583947A1 (en) 2004-10-12 2006-04-20 Forbes Medi-Tech (Research) Inc. Compounds and methods of treating insulin resistance and cardiomyopathy
US20080058395A1 (en) 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
WO2008118785A2 (en) 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
US20080241121A1 (en) 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
EP2677319B1 (en) * 2008-07-09 2015-12-30 The Institute for Ethnomedicine Antibody for detection of a neurotoxic amino acids associated with neurological disorders
WO2010132128A1 (en) * 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287204A1 (en) * 2002-06-19 2005-12-29 Hageman Robert J J Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE KONING, T. J. et al., 'Beneficial Effects of L-Serine and Glycine in the Management of Seizures in Phosphoglycerate Dehydrogenase Deficiency'. Annals of Neurology. 1998, vol. 44, no. 2, pages 261-265. *

Also Published As

Publication number Publication date
IL232710A0 (en) 2014-07-31
US11700840B2 (en) 2023-07-18
EP2782566A1 (en) 2014-10-01
EP2782566A4 (en) 2016-01-13
DK2782566T3 (da) 2021-02-08
US20140212893A1 (en) 2014-07-31
US20210153483A1 (en) 2021-05-27
US20130156846A1 (en) 2013-06-20
EP2782566B1 (en) 2021-01-06
WO2013078395A1 (en) 2013-05-30
US20220000082A1 (en) 2022-01-06
US20180027781A1 (en) 2018-02-01
CA2855854C (en) 2020-03-31
AU2012340563A1 (en) 2014-05-29
US12295353B2 (en) 2025-05-13
US11974551B2 (en) 2024-05-07
CA2855854A1 (en) 2013-05-30
US11917986B2 (en) 2024-03-05
JP2014534263A (ja) 2014-12-18
IL232710B (en) 2021-12-01
PT2782566T (pt) 2021-03-03
ES2856063T3 (es) 2021-09-27
JP6265908B2 (ja) 2018-01-24

Similar Documents

Publication Publication Date Title
US12295353B2 (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
US10434109B2 (en) Compositions for treating neurological disorders
Shen et al. Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract
US20180177745A1 (en) Application Of R-ketamine And Salt Thereof As Pharmaceuticals
JP2021152032A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
CA2785714A1 (en) Anaplerotic therapy for alzheimer's disease and the aging brain
US9931326B2 (en) Composition comprising torasemide and baclofen for treating neurological disorders
GB2571978A (en) Uses, compositions and methods
AU2019346024B2 (en) Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases
JPWO2013051266A1 (ja) タウ凝集阻害剤
EP4590304A1 (en) Methods of reducing neurodegeneration associated with neurodegenerative diseases
Lane et al. Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat
WO2020070557A1 (en) Modified therapeutic agent analogs of mefenamic acid
US10478511B2 (en) Therapeutic agent for tauopathy and method for screening thereof
Matthews The Potential Role of Sigma-1 Receptor in Combating Alzheimer's Disease
CN120459095A (zh) 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途
WO2023230560A1 (en) Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases
JP2024514533A (ja) 神経伝達に対する鏡像異性体選択的作用
Martin Exploring Alternative Therapeutic Interventions For The Treatment Of Leigh Syndrome
McCain Jr Impaired Metabolic Flexibility in a Mouse Model Of Leigh Syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)